{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:41:25Z","timestamp":1791031285992,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T00:00:00Z","timestamp":1361923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The role of compound heterozygous genetic haemochromatosis (<jats:styled-content style=\"fixed-case\">CHGH<\/jats:styled-content>) (<jats:styled-content style=\"fixed-case\">C282Y<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">H63D<\/jats:styled-content>) mutations in the manifestations of iron overload is known; however, the extent of these manifestations and their associated management remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study evaluates the phenotypic manifestations of <jats:styled-content style=\"fixed-case\">CHGH<\/jats:styled-content> using laboratory and radiological biomarkers including serum ferritin\/transferrin saturation, liver function tests (<jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content>), thyroid function tests, blood sugar level, and abdominal ultrasound (<jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>) or computed tomography. The study also evaluates the effects of venesection therapy on these markers and its potential role in routine management of <jats:styled-content style=\"fixed-case\">CHGH<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this case\u2010controlled study, 104 patients with <jats:styled-content style=\"fixed-case\">HFE\u2010C282Y\/H63D<\/jats:styled-content> compound mutations were subjected to laboratory investigations and imaging. Tests were repeated over a 4\u2010year period before and after venesection. Data were compared between patient and control groups using paired <jats:italic><jats:styled-content style=\"fixed-case\">t<\/jats:styled-content><\/jats:italic>\u2010tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients showed significantly higher serum ferritin and transferrin saturations compared with controls (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic> = 0.002, <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic> = 0.003). Twenty\u2010four patients (23%) demonstrated hyperferritinaemia \u22651000\u2009mmol\/<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>. Sixty\u2010nine patients (68%) demonstrated biochemical abnormalities on initial testing (abnormal <jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content> (transaminases) (51 patients, 74%) and <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\/computed tomography (42 patients, 61%)). A significant number of <jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> abnormalities normalised post\u2010venesection (80%; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic> = 0.000 and 52%; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic> = 0.005 respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Phenotypic manifestations displayed by <jats:styled-content style=\"fixed-case\">CHGH<\/jats:styled-content> patients can include biochemical and radiological abnormalities, which can occur at levels similar to <jats:styled-content style=\"fixed-case\">C282Y<\/jats:styled-content> homozygous disease (ferritin \u22651000\u2009mmol\/<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>). With venesection therapy, a large number of these abnormalities is reversible. Based on this, a non\u2010invasive framework to assess and manage <jats:styled-content style=\"fixed-case\">CHGH<\/jats:styled-content> within a routine community\u2010based clinical setting is proposed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1445-5994.2012.02937.x","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T13:20:13Z","timestamp":1347024013000},"page":"254-261","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phenotypic and clinical manifestations of compound heterozygous genetic haemochromatosis (<scp>CHGH<\/scp>): a non\u2010invasive approach to clinical management"],"prefix":"10.1111","volume":"43","author":[{"given":"R.","family":"Ramakrishna","sequence":"first","affiliation":[{"name":"Southern Sydney Haematology  Sydney"},{"name":"Graduate School of Medicine University of Wollongong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Southern Sydney Haematology  Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sarathy","sequence":"additional","affiliation":[{"name":"Southern Sydney Haematology  Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bowen","sequence":"additional","affiliation":[{"name":"Southern IML Pathology  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073286"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.26.061505.111226"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613000"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.17.2216"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(02)80116-0"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70134-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.07.009"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70320-8"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.029751"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2010.05.013"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22972"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.090605"},{"key":"e_1_2_8_14_1","first-page":"1961","article-title":"Nonalcoholic fatty liver disease","volume":"73","author":"Bayard M","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003547"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21827"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05002.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2002.01597.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-8-200304150-00008"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35343"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.3.309"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70482-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.285"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2008.078014"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2004.0953.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.09.2601"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(92)90060-3"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2012.02937.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2012.02937.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:04:20Z","timestamp":1697328260000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2012.02937.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,27]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/j.1445-5994.2012.02937.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2012.02937.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,27]]},"assertion":[{"value":"2012-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}